CYTOKINETICS INC

CYTK Net selling

CIK 0001061983 #898 in the set updated 17 Sep 2026

Bought (120 mo)

$3.28M

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$192.93M

$29.86M on a plan · $125.51M straight out of an exercise

Sold at will

$37.56M

156 of 689 sales

Net

−$189.65M

−$34.28M against sales at will

By person

32 insiders · 706 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Blum Robert I

President & CEO

—

$59.58M (226) scheduled

−$59.58M

286,876

0.2064%

$19.89M

+1,034%

Malik Fady Ibraham

EVP Research & Development

—

$32.65M (160) scheduled

−$32.65M

153,902

0.1107%

$10.67M

+1,010%

BVF PARTNERS L P/IL entity

See Explanaton of Responses

$3.23M (6)

$24.68M (6)

−$21.45M

463,244

0.3332%

$32.12M

−71.5%

Callos Andrew

EVP, Chief Commercial Officer

—

$18.98M (34) scheduled

−$18.98M

58,555

0.0421%

$4.06M

+2,362%

PARSHALL B LYNNE

Director

—

$8.68M (25) scheduled

−$8.68M

10,784

0.0078%

$747.65K

—

SMITH SANDFORD D

Director

—

$6.69M (35) scheduled

−$6.69M

18,801

0.0135%

$1.30M

—

Lee Sung

EVP, Chief Financial Officer

—

$5.70M (5) scheduled

−$5.70M

63,221

0.0455%

$4.38M

—

HENDERSON JOHN T

Director

$51.43K (1)

$5.75M (19) scheduled

−$5.70M

78,360

0.0564%

$5.43M

+11,791%

Kaye Edward M. MD

Director

—

$5.51M (10) scheduled

−$5.51M

10,434

0.0075%

$723.39K

—

Jaw Ching

SVP Finance & CFO

—

$4.99M (10) scheduled

−$4.99M

57,346

0.0412%

$3.98M

—

Cragg David

Chief HR & Admin Officer

—

$3.80M (10) scheduled

−$3.80M

153,233

0.1102%

$10.62M

+462.6%

COSTA SANTO J

Director

—

$3.00M (11) scheduled

−$3.00M

20,600

0.0148%

$1.43M

—

WIERENGA WENDALL

Director

—

$2.88M (12) scheduled

−$2.88M

32,345

0.0233%

$2.24M

—

GAGE L PATRICK

Director

—

$2.06M (22) scheduled

−$2.06M

28,932

0.0208%

$2.01M

+3.3%

SCHLOSSBERG MARK A

SVP - Legal & General Counsel

—

$2.05M (4) scheduled

−$2.05M

103,408

0.0744%

$7.17M

—

WIERENGA WENDELL

Director

—

$1.88M (3) scheduled

−$1.88M

35,563

0.0256%

$2.47M

+9.9%

Morgan Bradley Paul

SVP Drug Discovery & Early Dev

—

$1.77M (15) scheduled

−$1.77M

46,441

0.0334%

$3.22M

+166.5%

Wong Robert

VP, Chief Accounting Officer

—

$957.58K (4) scheduled

−$957.58K

18,655

0.0134%

$1.29M

+114.5%

McDowell Caryn Gordon

GC & Chief Compliance Officer

—

$574.51K (67) scheduled

−$574.51K

32,548

0.0234%

$2.26M

+415.6%

Harrington Robert Arthur

Director

—

$394.92K (6) scheduled

−$394.92K

21,932

0.0158%

$1.52M

—

Bhanji Muna

Director

—

$215.60K (3) scheduled

−$215.60K

26,361

0.0190%

$1.83M

—

Landry Robert E

Director

—

$146.79K (2) scheduled

−$146.79K

8,184

0.0059%

$567.40K

—

Hessekiel Jeffrey

Chief Legal & Admin Officer

—

—

—

107,943

0.0776%

$7.48M

—

WOLFF ANDREW A

SVP & CMO

—

—

—

47,255

0.0340%

$3.28M

+91.0%

Schnieders Elisabeth

Sr. VP, Business Development

—

—

—

43,919

0.0316%

$3.04M

+166.4%

BARBARI SHARON

EVP, Finance & CFO

—

—

—

40,323

0.0290%

$2.80M

+39.6%

Wysenski Nancy

Director

—

—

—

33,992

0.0245%

$2.36M

—

Pletcher Brett A

EVP, Chief Legal Officer

—

—

—

33,140

0.0238%

$2.30M

—

CHARPENTIER BONNIE

SVP Regulatory & Compliance

—

—

—

29,004

0.0209%

$2.01M

—

RODDY PETER S

SVP Finance & CAO

—

—

—

21,520

0.0155%

$1.49M

+1,316%

Califf Robert

Director

—

—

—

6,003

0.0043%

$416.19K

—

Daly James M

Director

—

—

—

3,390

0.0024%

$235.03K

—

Individual transactions

0

Nothing of that kind in this period.

What was left out

Form 4 filings counted 843

Amendments (4/A) skipped 6

Filings about a different issuer 0

Unreadable filings 0

Joint filings 4

Sales on a Rule 10b5-1 plan 71

Sales straight out of an exercise 462

Sales at will 156

Transactions with no price 0

Shares from compensation/vesting 6,809,817

Sales filed before the plan box existed 137

History held since 30 Dec 2016